Kidney Week

Abstract: SA-PO0425

Safety and Efficacy of GLP-1 Receptor Agonists Across the Full Spectrum of CKD: A Real-World Cohort Study

Session Information

• CKM: Clinical - Epidemiology and Outcomes
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Cardiovascular-Kidney-Metabolic Health

• 602 Cardiovascular-Kidney-Metabolic Health: Clinical

Authors

• Jewel, Nasir Hossain, Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom

Nasir Hossain Jewel, DrMed, MBBS

• Rony, Mohammad Rabiul Islam, Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom

Mohammad Rabiul Islam Rony, MBBS

• Alomari, Waleed Abdallah Dheif Allah, Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom

Waleed Abdallah Dheif Allah Alomari, MBBS

• Alawni, Tayseer, Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom

Tayseer Alawni, MD

• Wahba, Mona, Epsom and St Helier University Hospitals NHS Trust, London, United Kingdom

Mona Wahba, MA

Background

GLP-1 receptor agonists improve glycaemic control, weight, and cardiovascular risk in CKD, but evidence in dialysis and transplant recipients remains limited. We report real-world outcomes from an ethnically diverse renal unit.

Methods

Retrospective cohort study of patients commenced on GLP-1 receptor agonists at St Helier Renal Unit, 2024–2026. Groups: CKD 1–5 non-dialysis (n = 31), haemodialysis (n = 17), peritoneal dialysis (n = 2), renal transplant (n = 18). Outcomes compared from baseline to latest post-treatment measurement. Wilcoxon signed-rank test; IBM SPSS v29.

Results

68 patients (38 male, 30 female); median age 60 (IQR 54–68) and 64 (IQR 54–70) years respectively. Ethnicity: White British 50%, Asian 22%, Black African 19%, other 9%. Median duration 13 months (IQR 9–14). 93% of patients had Type 2 Diabetes and 72% were treated for Hypertension. BMI fell (−3.2 kg/m², −9.3%, p<0.001; n = 63); HbA1c fell from 60 to 48 mmol/mol (p<0.001; n = 57). Systolic BP fell from 140 to 130 mmHg (p = 0.008; n = 45). eGFR was stable in non-dialysis CKD and transplant patients (p = 0.86; n = 36). Urine PCR fell from 56 to 32 mg/mmol (−23%; p = 0.10, n = 28). LDL cholesterol fell (−0.3 mmol/L, −12%, p<0.001; n = 57). Insulin and oral antidiabetic drugs discontinued in 19.12%. Antihypertensive drug dose reduced or stopped in 20.4%. 15% patient had GI side effects and 7% patients discontinued the drug; There were 2 CV events (1 ischaemic stroke, 1 syncopal episode with ILR-detected pauses).

Conclusion

GLP-1 receptor agonists improved BMI, HbA1c, blood pressure, and LDL cholesterol across the CKD spectrum, with an acceptable safety profile. Randomized controlled trials are needed to assess long-term renal and cardiovascular benefits in dialysis and kidney transplant patients.

Change from baseline to latest available follow-up for each outcome.